Fezolinetant

Last updated

Fezolinetant
Fezolinetant.svg
Clinical data
Trade names Veozah, Veoza
Other namesESN-364
AHFS/Drugs.com Monograph
MedlinePlus a623051
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 51% [4] [ unreliable medical source? ]
Metabolism CYP1A2, (CYP2C9, CYP2C19 to lesser extent) [1]
Metabolites ES259564 [5]
Elimination half-life 9.6h [1]
Excretion Urine 76.9%, feces 14.7% [6] [ unreliable medical source? ]
Identifiers
  • (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C16H15FN6OS
Molar mass 358.40 g·mol−1
3D model (JSmol)
  • C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C
  • InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1
  • Key:PPSNFPASKFYPMN-SECBINFHSA-N

Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. [1] [7] It is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by for the treatment of sex hormone-related disorders.[ medical citation needed ] It is taken by mouth. [1] It is developed by Astellas Pharma which acquired it from Ogeda (formerly Euroscreen) in April 2017. [8] [9] [10]

Contents

The most common side effects include abdominal pain, diarrhea, insomnia, back pain, hot flush and elevated hepatic transaminases. [7]

Fezolinetant was approved for medical use in the United States in May 2023, [7] and in the European Union in December 2023. [2] [3] Fezolinetant is the first neurokinin 3 (NK3) receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause. [7] The FDA considers it to be a first-in-class medication. [11]

Medical uses

Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. [1] [2]

History

In May 2017, fezolinetant had completed phase I and phase IIa clinical trials for hot flashes in postmenopausal females. [10] Phase IIa trials in polycystic ovary syndrome patients are ongoing. [10]

In March 2023, results from SKYLIGHT 1, a Phase III clinical study of the treatment of moderate to severe hot flashes due to menopause, were published in The Lancet. [12] [13]

Fezolinetant shows high affinity for and potent inhibition of the NK3 receptor in vitro (Ki = 25 nM, IC50 Tooltip half-maximal inhibitory concentration = 20 nM). [9] Loss-of-function mutations in TACR and TACR3, the genes respectively encoding neurokinin B and its receptor, the NK3 receptor, have been found in patients with idiopathic hypogonadotropic hypogonadism. [9] In accordance, NK3 receptor antagonists like fezolinetant have been found to dose-dependently suppress luteinizing hormone (LH) secretion, though not that of follicle-stimulating hormone (FSH), and consequently to dose-dependently decrease estradiol and progesterone levels in females and testosterone levels in males. [14] As such, they are similar to GnRH modulators, and present as a potential clinical alternative to them for use in the same kinds of indications. [15] However, the inhibition of sex hormone production by NK3 receptor inactivation tends to be less complete and "non-castrating" relative to that of GnRH modulators, and so they may have a reduced incidence of menopausal-like side effects such as loss of bone mineral density. [14] [15]

Unlike GnRH modulators, but similarly to estrogens, NK3 receptor antagonists including fezolinetant and MLE-4901 (also known as AZD-4901, formerly AZD-2624) have been found to alleviate hot flashes in menopausal females. [16] [17] This would seem to be independent of their actions on the hypothalamic–pituitary–gonadal axis and hence on sex hormone production. [16] [17] NK3 receptor antagonists are anticipated as a useful clinical alternative to estrogens for management of hot flashes, but with potentially reduced risks and side effects. [16] [17]

The effectiveness of Veozah to treat moderate to severe hot flashes was demonstrated in each of the first 12-week, randomized, placebo-controlled, double-blind portions of two phase III clinical trials. [7] In both trials, after the first 12 weeks, the females on placebo were then re-randomized to Veozah for a 40-week extension study to evaluate safety. [7] Each trial ran a total of 52 weeks. [7] The average age of the trial participants was 54 years old. [7]

The FDA granted the application for fezolinetant priority review designation. [7] The approval of Veozah was granted to Astellas Pharma US, Inc. [7]

Society and culture

In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Veoza, intended for the treatment of hot flushes (vasomotor symptoms) associated with menopause. [2] The applicant for this medicinal product is Astellas Pharma Europe B.V. [2]

Fezolinetant was approved for medical use in the United States in May 2023, [7] and in the European Union in December 2023. [2] [3]

Brand names

Fezolinetant is the international nonproprietary name. [18]

Fezolinetant is sold under the brand names Veozah and Veoza. [1] [2]

Related Research Articles

Hot flashes are a form of flushing, often caused by the changing hormone levels that are characteristic of menopause. They are typically experienced as a feeling of intense heat with sweating and rapid heartbeat, and may typically last from two to 30 minutes for each occurrence.

<span class="mw-page-title-main">Selective estrogen receptor modulator</span> Drugs acting on the estrogen receptor

Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonist/antagonists (ERAAs), are a class of drugs that act on the estrogen receptor (ER). A characteristic that distinguishes these substances from pure ER agonists and antagonists is that their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues.

<span class="mw-page-title-main">Conivaptan</span> Chemical compound

Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia. The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.

<span class="mw-page-title-main">Bazedoxifene</span> Chemical compound

Bazedoxifene, used as bazedoxifene acetate, is a medication for bone problems and possibly for cancer. It is a third-generation selective estrogen receptor modulator (SERM). Since late 2013 it has had U.S. FDA approval for bazedoxifene as part of the combination drug Duavee in the prevention of postmenopausal osteoporosis. It is also being studied for possible treatment of breast cancer and pancreatic cancer.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

Neurokinin 1 (NK1) antagonists (-pitants) are a novel class of medications that possesses unique antidepressant, anxiolytic, and antiemetic properties. NK-1 antagonists boost the efficacy of 5-HT3 antagonists to prevent nausea and vomiting. The discovery of neurokinin 1 (NK1) receptor antagonists was a turning point in the prevention of nausea and vomiting associated with cancer chemotherapy.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, a severe form of arthritis in children, and COVID‑19. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

<span class="mw-page-title-main">Osanetant</span> Chemical compound

Osanetant (developmental code name SR-142,801) is a neurokinin 3 receptor antagonist which was developed by Sanofi-Synthélabo and was being researched for the treatment of schizophrenia but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s.

<span class="mw-page-title-main">Esmirtazapine</span> Drug formerly under development for treatment of menopause symptoms

Esmirtazapine (ORG-50,081) is a tetracyclic antidepressant drug that was under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.

<span class="mw-page-title-main">Bionovo</span> Biotechnology company

Bionovo was an American biotechnology company focused on the discovery and development of botanically derived treatments for women's health and cancer based in Emeryville, California. The company had multiple drug candidates in U.S. Food and Drug Administration (FDA) clinical trials- Menerba a selective estrogen receptor beta agonist for hot flashes associated with menopause Seala a selective estrogen receptor beta agonist for menopausal vaginal dryness and Bezielle for advanced breast cancer. The company has ceased activity after filing for Chapter 7 bankruptcy protection in California. Bionovo's stock is no longer listed.

Menerba, also known as Menopause Formula 101 (MF-101), is a botanical drug candidate that acts as a selective estrogen receptor modulator (SERM) which is being studied for its potential to relieve hot flashes associated with menopause. Menerba, an estrogen receptor beta (ERβ) agonist (ERBA), is part of a new class of receptor subtype-selective estrogens, which is selective in transcriptional regulation to one of the two known estrogen receptor (ER) subtypes. Menerba consists of 22 herbs that have been used historically in traditional Chinese medicine.

<span class="mw-page-title-main">Ospemifene</span> Chemical compound

Ospemifene is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy."

<span class="mw-page-title-main">Botanical drug</span> Plant ingredients marketed for treatment of a disease

A botanical drug is defined in the United States Federal Food, Drug, and Cosmetic Act as a botanical product that is marketed as diagnosing, mitigating, treating, or curing a disease; a botanical product in turn, is a finished, labeled product that contains ingredients from plants. Chemicals that are purified from plants, like paclitaxel, and highly purified products of industrial fermentation, like biopharmaceuticals, are not considered to be botanical products.

Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

<span class="mw-page-title-main">Relugolix</span> Chemical compound

Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is also under development for use in the treatment of endometriosis. It is taken by mouth once per day.

<span class="mw-page-title-main">Pavinetant</span> Chemical compound

Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.

<span class="mw-page-title-main">Zuranolone</span> Chemical compound

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. It is taken by mouth.

<span class="mw-page-title-main">Abrocitinib</span> Chemical compound

Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.

<span class="mw-page-title-main">Elinzanetant</span> Chemical compound

Elinzanetant (developmental code names BAY-3427080GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders". It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women. As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.

Waljit Dhillo is an endocrinologist and a Professor of Endocrinology & Metabolism at the Imperial College London. He is the Director of Research at the Division of Medicine & Integrated Care at Imperial College Healthcare NHS Trust and the Dean of the National Institute for Health and Care Research (NIHR) Academy. His research focuses on how the endocrine system controls body weight and reproductive functions.

References

  1. 1 2 3 4 5 6 7 "Veozah – fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.
  2. 1 2 3 4 5 6 7 "Veoza EPAR". European Medicines Agency (EMA). 7 December 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. 1 2 3 "Veoza PI". Union Register of medicinal products. 12 December 2023. Retrieved 26 December 2023.
  4. ↑ "Fezolinetant".
  5. ↑ https://classic.clinicaltrials.gov/ct2/show/NCT04793204
  6. ↑ "Fezolinetant". DrugBank.com.
  7. 1 2 3 4 5 6 7 8 9 10 11 "FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  8. ↑ "Astellas to Acquire Ogeda SA" (Press release). Astellas Pharma. Archived from the original on 5 November 2021. Retrieved 5 November 2021– via PR Newswire.
  9. 1 2 3 Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, et al. (July 2015). "Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)". ACS Medicinal Chemistry Letters. 6 (7): 736–740. doi:10.1021/acsmedchemlett.5b00117. PMC   4499830 . PMID   26191358.{{cite journal}}: CS1 maint: overridden setting (link)
  10. 1 2 3 "Fezolinetant – Ogeda". AdisInsight. Archived from the original on 5 November 2021. Retrieved 5 November 2021.
  11. ↑ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
  12. ↑ Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. (April 2023). "Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study". The Lancet. 401 (10382): 1091–1102. doi:10.1016/S0140-6736(23)00085-5. PMID   36924778. S2CID   257498379.{{cite journal}}: CS1 maint: overridden setting (link)
  13. ↑ "A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause (Skylight 1)". ClinicalTrials.gov . U.S. National Institutes of Health. 13 July 2022. Archived from the original on 29 March 2023. Retrieved 29 March 2023.
  14. 1 2 Fraser GL, Ramael S, Hoveyda HR, Gheyle L, Combalbert J (2016). "The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women". J. Clin. Endocrinol. Metab. 101 (2): 417–26. doi: 10.1210/jc.2015-3621 . PMID   26653113.
  15. 1 2 Fraser GL, Hoveyda HR, Clarke IJ, Ramaswamy S, Plant TM, Rose C, et al. (2015). "The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle". Endocrinology. 156 (11): 4214–25. doi: 10.1210/en.2015-1409 . PMID   26305889.{{cite journal}}: CS1 maint: overridden setting (link)
  16. 1 2 3 "Gone in a Flash: New Drug Class Targets Menopause Symptom". Medscape. Archived from the original on 12 May 2017. Retrieved 29 April 2017.
  17. 1 2 3 "Ogeda Announces Positive Data From Phase IIa Trial Of Fezolinetant In The Treatment Of Menopausal Hot Flashes". www.clinicalleader.com. Archived from the original on 6 January 2017. Retrieved 29 April 2017.
  18. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl: 10665/330984 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.